Drug Approval | December 20, 2022
Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Positive opinions based on significant survival benefit
Positive opinions based on significant survival benefit
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
This partnership stemmed from a successful customer-supplier relationship spanning several years.
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
The current ruling will assure the safety of the use of Ranitidine for Indian patients
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
GlobalData predicts the average prices of dual chamber pacemakers in both India and China are expected to reduce at an average CAGR of -3.42% from 2022 to 2025.
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
The use of procalcitonin testing for sepsis management is highest in the US
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
